Results 191 to 200 of about 6,042 (221)

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

The Lancet Gastroenterology and Hepatology, 2023
exaly  

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

Lancet, The, 2019
Kristian Reich, Susan Flavin, Bruce Randazzo   +2 more
exaly  

Brodalumab/guselkumab

Reactions Weekly, 2021
openaire   +1 more source

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis

New England Journal of Medicine, 2015
Kenneth B Gordon, Shu Li, Kristian Reich
exaly  

Belimumab/guselkumab

Reactions Weekly, 2020
openaire   +1 more source

Guselkumab/methotrexate/tozinameran

Reactions Weekly, 2022
openaire   +1 more source

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

Journal of the American Academy of Dermatology, 2017
Kristian Reich, Peter Foley, Michael Song   +2 more
exaly  

Guselkumab/secukinumab/ustekinumab

Reactions Weekly, 2022
openaire   +1 more source

Adalimumab/guselkumab/secukinumab

Reactions Weekly, 2023
openaire   +1 more source

A phase II trial of guselkumab for Crohn’s disease

Nature Reviews Gastroenterology and Hepatology, 2022
exaly